title: Impaired cognition in rats with cortical dysplasia: additional impact of early-life seizures.
abstract: One of the most common and serious co-morbidities in patients with epilepsy is cognitive impairment. While early-life seizures are considered a major cause for cognitive impairment, it is not known whether it is the seizures, the underlying neurological substrate or a combination that has the largest impact on eventual learning and memory. Teasing out the effects of seizures from pre-existing neurological disorder is critical in developing therapeutic strategies. We therefore investigated the additional cognitive effects of seizures on rodents with malformations of cortical development induced with methylazoxymethanol acetate. Pregnant rats were injected with saline or methylazoxymethanol acetate at embryonic Day 15 or 17 to induce differing malformation severity. From the day of birth to 9 days of age, half the pups received 50 flurothyl-induced seizures. All rats underwent testing in the Morris water maze to test spatial memory at 25 days of age (immediate post-weaning) or during adolescence at 45 days of age. Post-weaning rats had severe spatial cognitive deficits in the water maze and seizures worsened performance. In contrast, in animals tested during adolescence, there was no longer an additional adverse effect of seizures. We also investigated whether the severity of the structural abnormality and seizures impacted brain weight, cortical thickness, hippocampal area and cell dispersion area. The mean brain weight in control animals was greater than in rats exposed to methylazoxymethanol acetate at embryonic Day 17, which was greater than rats exposed to methylazoxymethanol acetate at embryonic Day 15. Rats exposed to methylazoxymethanol acetate at embryonic Day 15 had a thinner cortical mantle compared with rats exposed at embryonic Day 17 and control animals. The hippocampal area was similar in rats exposed at embryonic Days 15 and 17 but was smaller compared with controls. Methylazoxymethanol at embryonic Day 17 caused dispersion of the CA1-4 cell layers in the hippocampus, whereas methylazoxymethanol at embryonic Day 15 caused focal nodules in or above the CA1 layer, but the CA1-4 layers were intact and similar to control. Early-life seizures did not have a significant impact on any of these parameters. These observations indicate that the major factor responsible for the cognitive impairment in the rats with cortical dysplasia was the underlying brain substrate, not seizures. These findings have significant implications for the understanding of cognitive impairments in childhood epilepsy and suggest that early aggressive therapy of seizures alone may not be an adequate strategy for minimizing cognitive effects.
authors: Department of Neurology, Neuroscience Center at Dartmouth, Dartmouth Medical School, One Medical Center Drive, Lebanon, New Hampshire, USA.
authors: Marcella M
authors: MM
authors: Lucas
authors: Pierre-Pascal
authors: PP
authors: Lenck-Santini
authors: Gregory L
authors: GL
authors: Holmes
authors: Rod C
authors: RC
authors: Scott
references: Hippocampus. 2011 Apr;21(4):347-53
references: 20865725
references: J Neurochem. 1972 Feb;19(2):297-306
references: 5010077
references: Epilepsy Res. 2002 Aug;50(3):251-64
references: 12200216
references: Dev Med Child Neurol. 2006 Jun;48(6):519-25
references: 16700947
references: Brain Res Dev Brain Res. 1999 Dec 10;118(1-2):99-107
references: 10611508
references: Epilepsy Res. 1999 Apr;34(2-3):85-90
references: 10210022
references: Epilepsia. 2007 Apr;48(4):720-31
references: 17284294
references: Neurology. 2002 Apr 23;58(8 Suppl 5):S21-6
references: 11971129
references: Neurology. 1993 Apr;43(4):681-7
references: 8469322
references: Seizure. 2001 Jun;10(4):250-9
references: 11466020
references: Fed Proc. 1972 Sep-Oct;31(5):1536-9
references: 5066457
references: Physiol Rev. 1997 Jan;77(1):199-215
references: 9016302
references: J Neurosci. 2003 Dec 17;23(37):11505-15
references: 14684854
references: Epilepsia. 2007 Jan;48(1):201-4
references: 17241230
references: Epilepsia. 2007 Apr;48(4):713-9
references: 17437414
references: Biochem J. 1966 Feb;98(2):20C-22C
references: 5941330
references: Neuroscience. 1993 May;54(1):49-60
references: 8100048
references: Brain Res Dev Brain Res. 2001 Jul 23;129(1):27-38
references: 11454410
references: J Neurosci Methods. 1984 May;11(1):47-60
references: 6471907
references: Epilepsy Res. 2002 Nov;52(1):35-42
references: 12445958
references: Clin Neuropharmacol. 1986;9 Suppl 3:S8-18
references: 3594461
references: Stroke. 1995 Apr;26(4):644-9
references: 7709412
references: Exp Neurol. 2009 Jan;215(1):167-77
references: 19000675
references: J Int Neuropsychol Soc. 1997 May;3(3):252-9
references: 9161104
references: J Child Neurol. 2009 Jun;24(6):734-42
references: 19359255
references: Epilepsy Res. 2009 Aug;85(2-3):221-30
references: 19395239
references: Dev Med Child Neurol. 2000 May;42(5):319-27
references: 10855652
references: Ann Neurol. 1998 Dec;44(6):845-57
references: 9851428
references: Epilepsia. 2002 Sep;43(9):1062-71
references: 12199732
references: Epilepsia. 1985 Sep-Oct;26(5):395-400
references: 4043009
references: J Comp Neurol. 2006 Mar 1;495(1):133-48
references: 16432901
references: Epilepsy Res. 1996 Apr;23(3):189-94
references: 8739122
references: Epilepsy Behav. 2009 Jan;14(1):40-7
references: 18929683
references: Epilepsia. 2007 Jan;48(1):158-68
references: 17241223
references: Ann Neurol. 2010 Feb;67(2):250-7
references: 20225290
references: Exp Neurol. 2009 Jun;217(2):378-87
references: 19345685
references: Brain Res Dev Brain Res. 2001 Nov 26;131(1-2):73-83
references: 11718838
references: Fed Proc. 1972 Sep-Oct;31(5):1520-3
references: 4626772
references: Ann Neurol. 1994 Sep;36(3):425-33
references: 8080250
references: Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10263-8
references: 9707635
references: Lancet Neurol. 2008 Feb;7(2):151-60
references: 18207113